Signal active
Bio
Steve Hall is a Board Member at Kymera Therapeutics. He brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures.
Prior to joining Lilly Ventures, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder. There he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years. This novel orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008.
Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. There he was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75MM.
Steve is the author of more than 40 papers and 60 patents. He received his BS in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology.
Steve currently sits on the boards of FORMA Therapeutics, Hydra Biosciences, InnoCentive, and Cerulean Pharma. He also is a board observer at Avid Radiopharmaceuticals and Viamet.
Location
Indianapolis, Indiana, United States, North America
Social
Primary Organization
2001
71
19
27
1-10
Financial Services, Venture Capital, Impact Investing, Life Science, Innovation Management
Jobs history
0
N/A
Board and Advisor Roles
1
N/A
Invest in regions
Profile Resume
Steve Hall is the Venture Partner at Lilly Ventures, based in United States, North America. With a background in Financial Services, Steve Hall has a rich history of leadership and innovation. Steve Hall studied Ph.D Organic Chemistry @ Massachusetts Institute of Technology. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Investment portfolio
1
0
Personal investment
1
Annouced Date | Organization Name | Funding Round | Money Raised |
---|---|---|---|
Dec 08, 2020 | Pienza | Seed Round - Pienza | 5.1M |
Partner investment
17
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Oct 21, 2014 | - | Series D - Viamet Pharmaceuticals | Lilly Ventures | 60.0M |
Feb 03, 2015 | Lysosomal Therapeutics | Series A - Lysosomal Therapeutics | Lilly Ventures | 20.0M |
Mar 19, 2015 | Nimbus Therapeutics | Series B - Nimbus Therapeutics | Lilly Ventures | 43.0M |
Jun 05, 2018 | Nimbus Therapeutics | Series C - Nimbus Therapeutics | Lilly Ventures | 65.0M |
Exits
0
There is no exit available on this Profile
Invest in industries